Plasma Fractionation Market Size, Trends, Growth, Opportunities 2024-2032| CSL and Grifols, S.A., Kedrion S.p.A, Octapharma

The global plasma fractionation market size was valued at USD 32.83 billion in 2023. The market is projected to grow from USD 35.21 billion in 2024 to USD 62.83 billion by 2032, exhibiting a CAGR of 7.5% during the forecast period (2024-2032).

The plasma fractionation market plays a vital role in providing life-saving treatments for various conditions. This press release explores a recent key industry development, a leading segment, and the future outlook for this critical market.

𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂'𝗿𝗲 𝗠𝗶𝘀𝘀𝗶𝗻𝗴: 𝗚𝗲𝘁 𝗮 𝗙𝗿𝗲𝗲 𝗥𝗲𝗽𝗼𝗿𝘁 (𝗣𝗗𝗙) 𝗦𝗮𝗺𝗽𝗹𝗲: https://www.fortunebusinessinsights.com/enquiry/sample/plasma-fractionation-market-101614

𝗢𝗰𝘁𝗮𝗽𝗵𝗮𝗿𝗺𝗮'𝘀 𝗪𝗶𝗹𝗮𝘁𝗲 𝗥𝗲𝗰𝗲𝗶𝘃𝗲𝘀 𝗘𝘅𝗽𝗮𝗻𝗱𝗲𝗱 𝗙𝗗𝗔 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗳𝗼𝗿 𝗕𝗹𝗲𝗲𝗱𝗶𝗻𝗴 𝗣𝗿𝗼𝗽𝗵𝘆𝗹𝗮𝘅𝗶𝘀:

In a significant development for the plasma fractionation market, Octapharma AG secured extended approval from the U.S. Food and Drug Administration (FDA) in December 2023. This approval pertains to their plasma-derived product, wilate (von Willebrand Factor/Coagulation Factor VIII Complex). The new label expansion allows for routine prophylaxis, offering a broader treatment option for individuals with bleeding disorders. This advancement empowers healthcare professionals to proactively reduce the frequency of bleeding episodes in adults and children aged six and above, significantly improving their quality of life.

𝗧𝗼𝗽 𝗣𝗹𝗮𝘆𝗲𝗿𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗣𝗹𝗮𝘀𝗺𝗮 𝗙𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝗮𝘁𝗶𝗼𝗻 𝗠𝗮𝗿𝗸𝗲𝘁:

• CSL (U.S.)
• Grifols, S.A (Spain)
• Takeda Pharmaceutical Company Limited (Japan)
• Kedrion S.p.A (Italy)
• Octapharma (Switzerland)
• Bio Products Laboratory Ltd. (U.K.)
• Biotest AG (Germany)
• LFB (France)

𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝗿𝗶𝘃𝗲𝗿𝘀 𝗮𝗻𝗱 𝗥𝗲𝘀𝘁𝗿𝗮𝗶𝗻𝘁𝘀:

Several factors are propelling the plasma fractionation market forward:

• 𝗥𝗶𝘀𝗶𝗻𝗴 𝗗𝗲𝗺𝗮𝗻𝗱 𝗳𝗼𝗿 𝗣𝗹𝗮𝘀𝗺𝗮-𝗗𝗲𝗿𝗶𝘃𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀: An increasing number of conditions, like haemophilia and immune deficiencies, rely on plasma-derived therapies for treatment, driving the market growth.
• 𝗚𝗿𝗼𝘄𝗶𝗻𝗴 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗼𝗳 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲𝘀: Improved diagnostics and heightened awareness of rare diseases are leading to earlier diagnoses and a greater demand for specialized treatments.
• 𝗔𝗴𝗶𝗻𝗴 𝗣𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻: The rising elderly population is more susceptible to age-related conditions treatable with plasma-derived therapies.

However, certain limitations persist:

• 𝗦𝘁𝗿𝗶𝗻𝗴𝗲𝗻𝘁 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗥𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀: Meeting strict regulatory standards for plasma collection and fractionation can hinder market entry for new players and delay product availability.
• 𝗣𝗹𝗮𝘀𝗺𝗮 𝗖𝗼𝗹𝗹𝗲𝗰𝘁𝗶𝗼𝗻 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀: Maintaining a sufficient and safe plasma supply chain necessitates robust donor recruitment and collection strategies.
• 𝗛𝗶𝗴𝗵 𝗖𝗼𝘀𝘁 𝗼𝗳 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀: Plasma-derived therapies can be expensive, posing affordability concerns for patients and healthcare systems.

𝗙𝗼𝗿 𝗙𝘂𝗹𝗹 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲 𝗩𝗶𝘀𝗶𝘁: https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲:

For a comprehensive understanding of the plasma fractionation market, Fortune Business Insights' report offers an in-depth analysis on:

• 𝗠𝗮𝗿𝗸𝗲𝘁 𝗚𝗿𝗼𝘄𝘁𝗵 𝗣𝗿𝗼𝗷𝗲𝗰𝘁𝗶𝗼𝗻𝘀: The report provides detailed market size and growth forecasts for the plasma fractionation market over the forecast period.
• 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: The report segments the market based on product type (immunoglobulins, coagulation factors, albumin), application (neurology, immunology, infectious diseases), and end-user (hospitals, clinics, home healthcare settings).
• 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲:The report identifies key players in the market and analyzes their competitive strategies.
• 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: The report provides insights into the growth potential of plasma fractionation in different geographical regions.

𝗜𝗺𝗺𝘂𝗻𝗼𝗴𝗹𝗼𝗯𝘂𝗹𝗶𝗻𝘀 𝗟𝗲𝗮𝗱 𝘁𝗵𝗲 𝗠𝗮𝗿𝗸𝗲𝘁:

The immunoglobulin segment is expected to dominate the plasma fractionation market during the forecast period. Immunoglobulins are a class of proteins crucial for the immune system, and they play a vital role in treating various immune deficiencies and autoimmune disorders.

𝗔 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲:

The plasma fractionation market is a competitive space with established multinational companies vying for market share. Continuous research and development efforts focus on improving plasma fractionation technologies, expanding the range of plasma-derived therapies, and ensuring efficient and cost-effective treatments.

𝗧𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗣𝗹𝗮𝘀𝗺𝗮 𝗙𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝗮𝘁𝗶𝗼𝗻 𝗠𝗮𝗿𝗸𝗲𝘁:

The plasma fractionation market is poised for continued growth as advancements in technology, increased awareness of rare diseases, and an ageing population drive demand for life-saving plasma-derived therapies. Addressing challenges like regulatory hurdles and cost concerns will be crucial for ensuring wider accessibility to these vital treatments. With ongoing research and development, the future of this market holds significant promise for improving the lives of patients relying on plasma-derived therapies.

𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲 𝗧𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁 𝗔𝗰𝗰𝗼𝗿𝗱𝗶𝗻𝗴 𝗧𝗼 𝗬𝗼𝘂𝗿 𝗖𝗼𝗻𝘃𝗲𝗻𝗶𝗲𝗻𝗰𝗲: https://www.fortunebusinessinsights.com/enquiry/ask-for-customization/plasma-fractionation-market-101614

Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner, Pune-411045,
Maharashtra, India.
Phone:
U.S.:+1 833 909 2966 (Toll-Free)
U.K.: +44 808 502 0280 (Toll-Free)
APAC +91 744 740 1245
Email: sales@fortunebusinessinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

This release was published on openPR.